BioMedWire Stocks

Google Develops AI System to Leverage Sound in Detecting Lung Ailments

Health acoustic sounds contain useful health signals that have the potential to aid in health monitoring as well as disease diagnosis. Recently, scientists at Google Research, in collaboration with researchers at Zambia’s Center of Infectious Disease Research, developed an AI system that can use coughing sounds to diagnose lung disease.

The system, called Health Acoustic Representations (HeAR), is available as a preprint on arXiv.

The investigators started working on the system after healthcare professionals reported that over time, they had learned to tell which patients had coronavirus by how their coughs sounded. For their study, they used an approach similar to the one used to create large-language models. They began by converting human sounds such as a baby and adult coughing, throat clearing, panting, laughing, speaking and breathing, which were obtained from YouTube, into spectrograms.

Once this was done, the researchers blocked a portion of each sound then prompted the system to predict the missing part. This is similar to the way large-language models learn to predict the word that comes next in a sentence. This resulted in a foundation model that the investigators explained could be modified for use in a range of tasks. In their case, the investigators used the system to learn to detect coronavirus and tuberculosis infections.

The investigators compared the accuracy of their system using a standard scale with random guesses. They observed that one data set scored 0.645 on coronavirus detection and 0.739 on tuberculosis detection. This is better, especially when compared to results obtained from other AI systems.

In total, the investigators tested the system with 33 different tasks across six datasets.

In their report, the investigators noted that the reported performance for these tasks leveraged frozen embeddings and linear probes rather than fine-tuning the entire neural network. They then acknowledged that while more research was needed, acoustic testing could someday be used in physicians’ offices to diagnose various lung diseases.

Investigators involved in the study included Pauline Musumali, Solomon Chifwamba, Seke Muzazu, Kachimba Shamaoma, and Francesca Silwamba from Zambia’s Center for Infectious Disease Research; and Yun Liu, Aren Jansen, Rory Pilgrim, Ryan Ehrlich, Timo Kohlberger, Dan Ellis, Eduardo Fonseca, and Marc Wilson from Google Research.

Luyu Wang, Basil Mustafa, Chung-Cheng Chiu, Lucas Smaira and Eric Lau from Google DeepMind provided technical support, guidance and critical feedback to the investigators, while teams from Project Coswara and CoughVID provided datasets for research. The Google Research team also offered hardware and software infrastructure support. The investigators’ findings were reported in arXiv.

As these AI-supported detection tools are taken through the development and commercialization process, patients can rely on existing diagnostic instruments made by companies such as Astrotech Corp. (NASDAQ: ASTC) to obtain definitive diagnoses of any conditions afflicting the patients.

NOTE TO INVESTORS: The latest news and updates relating to Astrotech Corp. (NASDAQ: ASTC) are available in the company’s newsroom at https://ibn.fm/ASTC

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

New Photodynamic Therapy Offers Hope Against Brain Cancer

A planned preclinical study testing a light-activated therapy that helps to kill residual brain cancer cells after…

14 hours ago

Novel Yeast Cell Platform Promises to Expedite the Development of Immunotherapies

Researchers have developed a technological platform that leverages yeast cells to test and understand new cancer treatments…

2 days ago

The Anti-Dilution Playbook: How Earth Science Tech Inc. (ETST) Rewrote the OTC Capital Structure Narrative

The company has issued zero common shares since October 2023, marking a decisive break from…

2 days ago

Improving the Odds: How LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Is Working to Make Cancer Therapies More Effective

LIXTE’s lead compound, LB-100, targets PP2A, a central regulator of cancer cell survival and treatment…

3 days ago

Policy Expert Offers Suggestions for Curbing US Health Care Costs

According to recent data, health expenditures in the U.S. reached $5.3 trillion in 2024. That figure equates…

4 days ago

Soligenix Inc. (NASDAQ: SNGX) Builds Momentum in Fight Against Rare, Chronic Cancer

Although CTCL may progress slowly in its early stages, it remains a chronic and ultimately…

5 days ago